WELLESLEY HILLS, Mass., Oct. 16 /PRNewswire-FirstCall/ -- MacroChem will participate in the PIPEs Conference 2007 to be held at the Hilton New York on October 18 and 19. The company will have an exhibit table, located outside the Sutton Room, throughout each day of the conference. MacroChem's President and Chief Executive Officer, Robert J. DeLuccia, will provide a company overview, including discussion about MacroChem's lead product, EcoNail(R), which is currently in a fully enrolled Phase 2 clinical trial. DeLuccia will also discuss MacroChem's newly acquired rights to pexiganan, a novel, topical anti-infective drug for treatment of diabetic foot infection (DFI), and its recent preferred stock conversion and private placement.
The PIPEs Conference will be a mix of education and networking with active investors in the small cap equity market. Two full days of programming will provide insight on industry developments from experts in the field, as well as networking opportunities with institutional investors, investment bankers, corporate attorneys, company executives, financial analysts, and media representatives from around the globe.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA(R), MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, http://www.macrochem.com.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.
bpatriacca@macrochem.comcberni@investorrelationsgroup.com, jtriunfo@investorrelationsgroup.combdouglass@investorrelationsgroup.commheller@investorrelationsgroup.com
CONTACT: Bernard Patriacca, VP-CFO of MacroChem, +1-781-489-7310,
bpatriacca@macrochem.com; or Investors, Christine Berni,
cberni@investorrelationsgroup.com, or Joseph Triunfo,
jtriunfo@investorrelationsgroup.com, both of The Investor Relations Group,
Inc., +1-212-825-3210, for MacroChem; Media, Bill Douglass,
bdouglass@investorrelationsgroup.com, or Michaela Heller,
mheller@investorrelationsgroup.com, both for MacroChem, +1-212-825-3210
Web site: http://www.macrochem.com/
